𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevention of relapse by mesalazine (Pentasa®) in pediatric Crohn's disease: A multicenter, double-blind, randomized, placebo-controlled trial

✍ Scribed by J.-P. Cezard; A. Munck; O. Mouterde; A. Morali; C. Lenaerts; A. Lachaux; D. Turck; J. Schmitz; C. Maurage; J.-P. Girardet; D. Belli; T. Lamireau; J. Sarles; J.-P. Chouraqui; B. Descos; A. Dabadi; M. Meyer; J.-P. Olives; J.-Y. Mary

Book ID
113634757
Publisher
Masson Editeur
Year
2009
Tongue
French
Weight
961 KB
Volume
33
Category
Article
ISSN
0399-8320

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des